WASID


Also found in: Acronyms.

WASID

A clinical trial–Warfarin-Asprin Symptomatic Intracranial Disease
Mentioned in ?
References in periodicals archive ?
Enrollment in the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) clinical trial ended early because of the high rate of serious adverse events in the warfarin patients.
Ralph Sacco, M.D., an investigator in the Northern Manhattan Stroke Study, noted in an interview that the findings from the WASID trial add weight to existing data that already tend to dispel beliefs about the benefit of warfarin for certain stroke populations.
Enrollment in the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial ended early because of the high rate of serious adverse events in the warfarin patients.
This was clearly demonstrated in two government- sponsored studies, the Warfarin Aspirin Recurrent Stroke Study (WARSS) and the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial, as well as in the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT).